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bstract
It has long been known that the major histocompatibility complex (MHC) is essentially involved in genetic susceptibility to ankylosing spondylitis
AS). The HLA-B27 antigen has been accounted for 20 to 50% of the total genetic risk for this disease. However, susceptibility to AS cannot be fully
xplained by associations with the MHC. Recent studies including linkage analyses as well as candidate gene and, most recently, genome-wide
ssociation studies indicate significant associations of the interleukin-1 gene cluster, interleukin-23 receptor and ARTS1 genes as well as otherD 
P
ossible loci with AS. In the murine model of proteoglycan-induced spondylitis, two susceptibility loci termed Pgis1 and Pgis2 were identified.
hus, AS is not a single-gene disease and the involvement of multiple non-MHC genes may account for the individual as well as geographical
ifferences seen in AS.
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. Introduction
Ankylosing spondylitis (AS) is the prototype of spondy-
oarthropathies (SpA), a group of inflammatory rheumatic
iseases with shared genetic background as well as common
linical features [1]. Family clustering is an important feature of
S that suggests the role of genetic factors in susceptibility to AS
2,3]. For example, in families of SpA patients, additional SpA
ases occur mostly among HLA-B27+ relatives [4,5]. Regard-
ng twin studies in AS, in a Finnish study, the concordance was
0% between monozygotic twins, 15% overall among dizygotic
wins and 20% among HLA-B27+ dizygotic twins [6]. Differ-
nces in concordance rates between monozygotic and dizygotic
wins indicate the crucial role of genetic factors in susceptibilityUN
C
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o AS [6].
Considering the role of genes, the major histocompatibility
omplex (MHC) alone is not sufficient to explain the heritabil-
∗ Corresponding author.










297-319X/$ – see front matter © 2009 Published by Elsevier Masson SAS on behal
oi:10.1016/j.jbspin.2009.02.006studies; Genome-wide association studies
ty of AS. While more than 90% of Caucasian AS patients
re HLA-B27+, only less than 5% of HLA-B27+ members of
he general population develop AS [7–9]. Thus, HLA-B27 has
een accounted for only approximately 20 to 50% of the overall
enetic susceptibility to AS [10,11].
Although the etiology of the disease is unknown, envi-
onmental and genetic components have been implicated as
redisposing factors. The dominant genetic component is the
lass I MHC encoded human leukocyte antigen HLA-B27, but
he presence of HLA-B27 alone is insufficient for disease devel-
pment [2–4,11,12]. There are two major hypotheses which
xplain the association of HLA-B27 with AS. The receptor the-
ry assumes that certain T cell receptors can recognize a complex
f foreign and MHC self peptides when together, but this putative
athogenic peptide is unknown [2–4]. The molecular mimicry
ypothesizes that microorganisms which partially resemble or
ross-react with HLA molecules are the source of antigenic com-
onents. This hypothesis of molecular mimicry targeted mostlyackground of ankylosing spondylitis. Joint Bone Spine (2009),
lebsiella and Yersinia antigens, but no appropriate microor- 55
anisms have yet been identified in patients with AS [11,13]. 56
herefore, extensive studies have been undertaken to identify 57
ther non-MHC genetic factors and, indeed, approximately a 58
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ozen chromosome regions or gene clusters have been linked to
S [2–4].
Linkage analysis, genome-wide screening and candidate
ene association studies have led to the identification of sev-
ral non-MHC chromosome regions possibly linked to AS [2,3].
ome of these loci, such as the interleukin-1 (IL-1) gene cluster
as been consistently reported by independent research groups
2,14]. Others, such as the genes of Aminopeptidase Regulator
f TNF receptor Shedding 1 (ARTS1) (also known as Endo-
lasmic Reticulum-associated Aminopeptidase 1 [ERAP1]) and
L-23 receptor (IL-23R) have been described by the Wellcome
rust Case-Control Consortium (WTCCC) study group that
ad formerly performed the genome-wide association study of
4,000 cases of seven common diseases [15,16]. Yet, less infor-
ation is available regarding the genetics of AS in comparison
o, for example, rheumatoid arthritis (RA).
Despite of the increasing amount of data about genetic con-
ributors, AS is a multifactorial disease, where the “conspiracy”
f genes and environmental factors lead to the development of
he well-known clinical symptoms. In this review, we summa-
ize data on the genetic basis of AS based on both human and
odents studies. We will review the most relevant information
n HLA as well as non-MHC alleles.
. Role of HLA-B27 and other major histocompatibility
omplex genes
The association between HLA-B27 and AS was first reported
n the early 1970s [17,18]. The prevalence of HLA-B27 is about
to 8% in the general population and more than 90% among AS
atients [3,7]. As estimated by linkage analysis as well as HLA-
27-dependent multiplicative model, the genetic contribution of
LA-B27 is about 20 to 35% [10,11,19–21]. The concordance
ates for HLA-B27+ mono- and dizygotic twins are 63 and 23%,
espectively [6].
Although there is no doubt that HLA-B27 is the major sus-
eptibility gene for AS, its mechanism of action is still not
nown. All manifestations of SpA spontaneously develop in
LA-B27 transgenic rats indicating a direct role of this gene
n disease susceptibility [22]. Among the 25 known HLA-B27
lleles, HLA-B*2705, the predominant allele in the Caucasian
opulation, may be the original allele and all other alleles may be
erived from HLA-B*2705 by mutation. Most allelic mutations
ffect the variable region and thus result in altered interactions
etween T cell receptors and antigenic peptides [23]. While most
ther HLA-B27 alleles have been associated with SpA, HLA-
*2706 and HLA-B*2709 occurring in South-East Asia and
ardinia, respectively, show no association with SpA [23].
In HLA-B alleles that confer susceptibility to SpA, a presence
f glutamic acid at position 45 and that of cysteine at position
7 of the HLA-B molecule is the specific pattern present in
ll alleles associated with SpA but absent in SpA-independent
lleles. Based on these structural alterations, functional theoriesU
Please cite this article in press as: Végvári A, et al. The genetic b
doi:10.1016/j.jbspin.2009.02.006
ave emerged. The arthritogenic peptide theory suggests that this
olecular structure enables the presentation of specific peptides
hat induce an autoimmune response. Regarding the impaired
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eines at position 67 resulting in altered intracellular trafficking
f the molecules [24,25].
MHC genes other than HLA-B may also be involved in the
evelopment of SpA. These genes may include class II MHC
lleles (HLA-DR genes), tumor necrosis factor- (TNF-) and
omplement genes as well as some genes involved in antigen
resentation by class I MHC molecules including TAP, LMP2
nd LMP7 [2–4]. Unfortunately, the predominant role of HLA-
27 highly influences the interpretation of these results as the
eported associations may rather be attributable to linkage dis-
quilibrium between the mentioned loci and HLA-B27. Only
he direct additional effect of HLA-DR4 has been confirmed in
LA-B27+ relatives of SpA patients [24].
. Non-major histocompatibility complex alleles in
nkylosing spondylitis
As discussed above, MHC accounts for less than 50% of
he genetic risk for AS. Various techniques have been used to
tudy the contribution of non-MHC genes to susceptibility to
nd severity of human AS [2–4] (Table 1).
Animal models are invaluable aids for the research of human
autoimmune) disorders. The ank/ank mouse has a loss-of-
unction mutation in the ank gene and develops a progressive
pA, similar to human AS [19,26], but the ank gene, either
n humans or mice, is not involved in autoimmune processes
26,27]. Other models of SpA have been developed in HLA-
27 transgenic rodents [21], or in transgenic mice expressing a
utant type IX collagen or a truncated form of TNF- [28]. In
ddition to human data, proteoglycan (PG)-induced spondyli-
is (PGIS), an autoimmune murine model of SpA will also be
riefly discussed [29,30].
. Linkage studies
Linkage exists when a candidate gene and another known
ocus are very close to each other, therefore, the two loci are
ransmitted together. Such linkage studies can be carried out in
arge families with many family members affected by a given dis-
ase. In these studies, results are presented as a non-parametric
inkage score (NPL), which is then converted to a log odds ratio
LOD) score. High LOD values (LOD ≥ 3.6) indicate signifi-
ant associations, while LOD greater or equal to 2.2 values are
uggestive [31].
There have been four large linkage studies with respect to
usceptibility to AS. In the North-American Spondylitis Consor-
ium (NASC) study, 185 families with 255 affected sibling pairs
ere analyzed. The most significant associations were attributed
o the MHC locus located on chromosome 6 (LOD = 15.6) and a
ingle non-MHC locus on chromosome 16 (LOD = 4.7). Other
oci with suggestive LOD values were located on chromosomes
, 3, 4, 5, 10, 11, 17 and 19 [19]. In the French AS genetics
ohort (GFEGS), 180 families with 244 affected sibling pairsackground of ankylosing spondylitis. Joint Bone Spine (2009),
ere assessed. Again, the MHC locus had the strongest linkage 163
21]. Also in this cohort, a region on the short arm of chromo- 164
ome 9 was significantly associated with acute anterior uveitis 165
ut not with AS [21]. Two studies from Oxford studies confirmed 166
D
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Table 1
Associations of non-major histocompatibility genes with ankylosing spondylitis.
Type of study Genetic linkage Reference(s)
Genome-wide association studies (WTCCC) Interleukin-23 receptor (IL-23R; chromosome 1)a [15,16]
ARTS1 (chromosome 5)a [15,16]
Candidate gene association studies Interleukin-1 gene cluster (IL-1A, IL-1B, IL-1RN) (chromosome 2)a [14,35,36,38–41]



















































































TCCC: Wellcome Trust Case-Control Consortium
a Confirmed strong association.
he strongest linkage with the MHC region and suggested link-
ge with loci on chromosomes 2, 3, 9, 10, 11, 16 and 19 [26]
Table 1).
A pooled meta-analysis indicated the most clear evidence for
inkage to MHC on chromosome 6. Additional strong linkage
as observed with regions on chromosomes 16 and 10, while
oderate linkage was seen with loci on chromosomes 2, 3, 4, 5,
, 11 and 17 [14].
Some loci were also associated with disease activity and
unctional severity. While MHC showed no linkage, regions on
hromosome 18 were significantly associated with the BASDAI
core. In addition, regions on the long arm of chromosome 2
xerted suggestive linkage with the BASFI functional impair-
ent score [27].
. Candidate gene associations
There have been conflicting results regarding the IL-1 gene
luster. This gene complex is located on chromosome 2 and
ncludes genes encoding IL-1 (IL-1A), IL-1 (IL-1B), IL-1
eceptor antagonist (IL-1RN) and other genes (IL1F5.IL1F10)
32]. This gene cluster corresponds to the region on chromosome
identified in linkage studies described above [14,26]. IL-1
nd IL-1 are pro-inflammatory cytokines primarily produced
y monocyte/macrophages, which stimulate the release of other
nflammatory mediators including prostaglandins, matrix met-
lloproteinases and other cytokines as well as the expression of
arious adhesion receptors [33,34]. IL-1Ra competitively block
he binding of IL-1 and IL-1 to their receptor and thus antago-
ize the effects of these cytokines [34]. While early small studies
uggested association between AS and the IL-1RN gene encod-
ng IL-1Ra [35,36], further larger studies could not confirm this
ssociation [37–39]. However, some small studies and a recent
eta-analysis showed higher carriage of a variable nucleotideU
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andem repeat (VNTR) in intron 2 of the IL-1RN gene in AS
atients compared to controls [35,36,40]. Moreover, two SNP
n exon 6 of the IL-1RN gene were also associated with AS [40].







he IL-1A and IL-1B genes exerted significant associations with
S [39,41]. Among these SNP, SNP rs3783526 in the IL-1A and
s1143627 in the IL-1B gene showed the most significant associ-
tions [39]. In addition, SNP rs2856836, rs17561 and rs1894399
n the IL-1A gene also showed very strong associations [41]
Table 1).
. Genome-wide association studies
As described above, the WTCCC initiative identified two new
oci strongly associated with AS, IL-23R and ARTS1 [15,16]
Table 1). IL-23R has been implicated in the pathogenesis of
A, psoriasis and inflammatory bowel diseases (IBD) [42–44].
L-23 is a potent pro-inflammatory cytokine that stimulates the
eneration of Th17 cells as well as the production of other
ytokines including TNF-, IL-6, IL-17 and IL-22. The gene
or the IL-23R protein is located on chromosome 1. Susceptibil-
ty to Crohn’s disease and psoriasis has been associated with the
NP rs11209026 [42,43]. In addition, SNP rs7530511 is also
ssociated with psoriasis [43]. Apart from the SNP mentioned
bove, several other SNP including rs10889677 and rs2201841
lso had significantly increased prevalence in Crohn’s disease
n comparison to controls [42]. We have recently confirmed
hat SNP rs10889677 and rs2201841 are not only associated
ith IBD, but also with RA [44]. In the WTCCC cohort, eight
L-23R SNP were genotyped in 1000 AS patients and 1500
ontrols. Seven out of these eight SNP showed association
ith AS. Highly significant associations were found with SNP
s11209032, rs11209026 and rs10489629 [16,45]. Associations
etween IL-23R gene polymorphisms and AS have recently
een confirmed in a Spanish cohort [46]. The IL-23R gene is
esponsible for 9% of the population-attributable risk of AS
15,16].
As far as ARTS1 is concerned, this protein is an aminopep-ackground of ankylosing spondylitis. Joint Bone Spine (2009),
idase in the endoplasmic reticulum. ARTS1, also known as 235
RAP1, cleaves receptors for cytokines including TNF- (TNF- 236
1), IL-1 (IL-1R2) and IL-6 (IL-6R) from the cell surface 237
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eptides to optimal length for antigen presentation [48]. The
hree genes encoding ARTS1 are located on chromosome 5 [49].
n the WTCCC cohort and follow-up studies, five SNP includ-
ng rs27044, rs30187, rs17482078, rs10050860 and rs2287987
ere associated with AS [16]. In addition, there is no associ-
tion between any ARTS1 SNP and either Crohn’s disease or
lcerative colitis [16]. Thus, ARTS1 may not be involved in the
athogenesis of various SpA but its effects may be specific for
S within the SpA family. The ARTS1 gene is responsible for
6% of the overall risk of AS [15,16].
. Other genes with unconﬁrmed associations
As discussed above, the associations of IL-1 cluster genes,
L-23R and ARTS1 genes have been confirmed in large cohorts.
here have been small studies suggesting the associations of
ther genes with AS.
Some alleles of the cytochrome P450 CYP2D6 gene located
n chromosome 22 have been weakly associated with AS [50].
here have been controversies regarding possible associations of
S with the transforming growth factor- (TGF-), ANKH and
oll-like receptor 4 (TLR4) genes. While some studies suggested
arginal associations of these genes with AS [51–53], other
tudies could not confirm this [54–56]. Finally, NOD2/CARD15
utations have been associated with Crohn’s disease, however,
everal studies confirmed that there were no such associations
ith AS [57].
. Lessons from the proteoglycan-induced spondylitis
odel
Polyarthritis and spondylitis can be induced in suscepti-
le mouse strains by immunization with human cartilage PG
58,59]. PGIS shows similarities to AS in terms of clinical and
adiological features. PGIS was induced in susceptible BALB/c
nd C3H/HeJCr (C3H) strains of mice, and in their F1 and
2 generations derived from intercrosses with arthritis- and/or
pondylitis-resistant DBA/2 and DBA/1 parent strains, by sys-
emic immunization with cartilage PG. Almost all (97–100%)
G-immunized BALB/c and C3H mice developed peripheral
rthritis by 2 weeks after the third antigen injection. Massive
nflammatory cell infiltration, pannus formation, and cartilage
nd bone erosion characterized the histopathologic picture of
he affected joints. None of the DBA/1 or DBA/2 parents nor
he (BALB/c × DBA/2) F1 hybrids developed arthritis until the
nd of the 14–18-week experimental period. The incidence and
everity of spondylitis were highly comparable in both PGIS-
usceptible inbred strains (BALB/c and C3H) [29].
Although F1 hybrids of the BALB/c × DBA/2 intercross
ere fully resistant to peripheral PGIA, unexpectedly, more than
0% of them developed PGIS, whereas none of the F1 hybrids
f BALB/c × DBA/1 developed PGIS [23]. These observationsU
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uggest that the DBA/1 strain carries very strong protective
enes against SpA, while the DBA/2 genome may contain both
pondylitis susceptibility and protective genes that might be




pine xxx (2009) xxx–xxx
Quantitative trait analysis was used in order to identify and
haracterize non-MHC chromosome loci that may be highly
ssociated with the development of PGIS [30]. Two major
oci exerted highly significant linkage, accounting for 40%
f the trait variance in the BALB/c × DBA/2 F2 generation.
he dominant spondylitis-susceptibility allele for the Pgis2
ocus (mouse chromosome 2) was derived from the BALB/c
train, whereas the Pgis1 (chromosome 18) recessive allele
as present in the arthritis-resistant DBA/2 strain. The Pgis1
ocus significantly affected the disease-controlling Pgis2 locus,
nducing as high incidence of spondylitis in F2 hybrids as
as found in the spondylitis-susceptible parent BALB/c strain.
dditional disease-controlling loci with suggestive linkage were
apped to the chromosomes 12, 15, and 19. A major locus
ontrolling IL-6 production was found on chromosome 14
lose to the gene of osteoclast differentiation factor Tnfsf11.
ocus on chromosome 11 near the Stat3 and Stat5 genes
ontrolled serum levels of the immunoglobulin IgG2a iso-
ype. The two major genetic loci Pgis1 and Pgis2 of murine
pondylitis were homologous to chromosome regions in human
enome, which control AS in human patients [30]. The first
urine locus (Pgis1) is homologous to human chromosomes
q and 18q, both of which have significant linkage with AS
ound in British and European kindreds [19,27,60]. The Pgia2
ocus overlaps with the cluster of IL-1 and Arts genes impli-
ated in susceptibility to AS in humans as described above
2,15,16,38].
. Conclusions
It is evident that the MHC, especially HLA-B27, plays a cen-
ral role in susceptibility to AS. For example, HLA-B27 confers
pproximately 20 to 50% of the total genetic risk for this dis-
ase. However, AS is definitely not a single gene disease and the
enetic background of AS cannot be fully explained by associa-
ions with the MHC. Candidate gene and, recently, genome-wide
ssociation studies have confirmed the strong association of IL-
cluster on chromosome 2, IL-23R gene on chromosome 1 and
RTS1 genes on chromosome 5 with AS. Linkage analysis con-
rmed possible associations with other regions. The strongest
inkage was observed for loci on chromosome 16, while mod-
rate linkage was suggested at sites on chromosomes 3, 10, 11,
7 and 19. In the PGIS animal model, two susceptibility loci
ermed Pgis1 and Pgis2 were identified.
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